で公開中です！詳しく見る

Boundless Bio

BOLD

時価総額 $5407万

2.34 USD

-0.01

0.43%

終値時点更新済み 10月16日 16:00 EDT

1日

-0.43%

5日間

-7.51%

1か月

-17.02%

3か月

-6.02%

6か月

43.56%

年初来

91.8%

1年

65.96%

5年間

-83.58%

10年間

-83.58%

概要： Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

従業員数： 28

ヘルスケアバイオテクノロジー

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 0%

ニュートラル 100%

ネガティブ 0%

ニュートラル

Serapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin Deficiency

- Daphne Karydas appointed as President and Chief Financial Officer - Weston Miller, MD, appointed as Chief Medical Officer - Additional appointments: Nina Hunter, PhD, as Chief Development Officer and Shiva G. Fritsch as Chief Corporate Affairs Officer - Lead program SERP-01 on track for Phase 2/3 initiation in late 2026 or early 2027 NEW YORK, Sept.

Serapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin Deficiency

ニュートラル

Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer

Veteran biotech executive to lead company growth as it advances multiple dual-payload ADCs through clinical development for people living with cancer Piers Ingram, PhD, Co-Founder, transitions to Senior Advisor and continues to serve on the Board of Directors; Jerome Boyd-Kirkup, PhD, founding Chief Scientific Officer, transitions to Senior Scientific Advisor SAN DIEGO and SEATTLE and SINGAPORE, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Callio Therapeutics (“Callio” or “the Company”), a clinical-stage biotechnology company advancing dual-payload antibody-drug conjugates (ADCs) as the next frontier of rationally designed targeted cancer therapy, today announced the appointment of Zachary (“Zach”) Hornby as Chief Executive Officer.

Callio Therapeutics Appoints Zachary Hornby as Chief Executive Officer

ニュートラル

Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

Halper Sadeh LLC is Investigating Whether BOLD and NDRA are Obtaining Fair Deals for their Shareholders

ニュートラル

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)

NEW YORK, June 23, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Boundless Bio, Inc. (NASDAQ: BOLD ) related to its merger with Serapha Bio, Inc. Upon closing of the proposed transaction, Boundless Bio shareholders are expected to own approximately 3.7% of the combined company.

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Boundless Bio, Inc. (NASDAQ: BOLD)

ニュートラル

BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the merger of Boundless Bio, Inc. (NASDAQ: BOLD) and Serapha Bio, Inc. Upon closing of the proposed transaction, Boundless Bio shareholders are expected to own approximately 3.7% of the combined company.Halper Sadeh encourages Boundless Bio shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.

BOLD Stock Alert: Halper Sadeh LLC is Investigating Whether Boundless Bio, Inc. is Obtaining a Fair Price for its Shareholders

ニュートラル

Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement

Combined company to operate as Serapha Bio and to advance Serapha's potential best-in-class in vivo base editing program for Alpha-1 Antitrypsin Deficiency

Boundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private Placement

ニュートラル

Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights

Enrollment proceeding in KOMODO-1 first-in-human clinical trial of BBI-940 $93 million in cash provides runway through expected clinical proof-of-concept readout for KOMODO-1 SAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fiscal quarter ended March 31, 2026. “We are encouraged by the progress of the KOMODO-1 trial," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio.

Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights

ニュートラル

Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers Findings support the ongoing Phase 1 clinical development of BBI-940, an oral, selective kinesin degrader, as a potential first-in-class therapy for select advanced or metastatic breast cancers

Boundless Bio Presents Preclinical Breast Cancer Data from its Oral Kinesin Degrader Program at 2026 AACR Annual Meeting

ポジティブ

Boundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degrader

Boundless Bio offers a highly asymmetric risk/reward profile, trading at a $25M valuation with $107.6M in cash and a runway into 2H 2028. BBI-940, BOLD's first direct ecDNA-targeting asset, is entering clinical trials with promising preclinical efficacy, high selectivity, and a rational mechanism of action. Previous clinical failures (BBI-825, BBI-335) targeted indirect vulnerabilities, but BBI-940 directly eliminates ecDNA, addressing a novel and validated cancer resistance mechanism.

Boundless Bio: An Underestimated Biotech With A First-In-Class EcDNA Targeted Kinesin Degrader

ニュートラル

Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced an upcoming poster presentation on their oral Kinesin degrader program at the American Association for Cancer Research (AACR) Annual Meeting 2026, which is being held April 17 – 22, in San Diego, CA.

Boundless Bio Announces Upcoming Presentation of Oral Kinesin Degrader Program at the American Association for Cancer Research Annual Meeting 2026

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています